Company / Shareholders' Equity
Actinium Pharmaceuticals, Inc. Shareholders' Equity History
FY2011-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Shareholders' Equity
$7.8M
FY2025
5-year range
$7.8M / $73.5M
FY2021-FY2025
Trend
-78.5%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Shareholders' Equity has declined for 3 consecutive years, from $74M in FY2022 to $8M in FY2025.
Based on SEC 10-K filings.
$8M in FY2025 with a 3-year CAGR of -52.6%.
Declined from $66M to $8M over the past 2 years.
Shareholders' Equity over time
Growth rates
- 3-Year CAGR
- -52.6%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- Actinium Pharmaceuticals, Inc.'s shareholders' equity has declined for 3 consecutive years.
- 3-year CAGR of -52.6%, indicating a declining trend.
- In FY2025, shareholders' equity decreased 78.5% year-over-year.
- Peak shareholders' equity was recorded in FY2022.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -8.23 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Shareholders' EquityValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $7.8M | -78.5% |
| FY2024 | $36.4M | -45.3% |
| FY2023 | $66.5M | -9.6% |
| FY2022 | $73.5M | +0.0% |
| FY2021 | $73.5M | +7313.7% |
| FY2011 | $992.0K | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026